Exkivity (Mobocertinib 40 Mg Capsule)

Exkivity (Mobocertinib 40 Mg Capsule) may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.

Common side effects include:

• Diarrhea
  
• Vomiting
  
• Nausea
  
• Decreased appetite
  
• Rash
  
• Dry skin
  
• Skin infection around nails
  
• Tiredness
  
• Mouth sores
  
• Muscle or joint pain

Contact your healthcare provider if you face any unusual or persistent side effects.

• The dosage and treatment duration of the Exkivity are decided by the doctor according overall patient's health.
• However the usual dose of this medicine is 160 mg orally once daily.
• This tablet should be taken with or without food, but at the fix time every day to get effective results.
• Don't miss a dose or overdose on the medicine.

• Exkivity is a targeted anticancer medicine with active ingredient Mobocertinib which belongs to tyrosine kinase inhibitor (TKI) class of drugs.
• This medicine works by binding and inhibiting the Epidermal growth factor receptor (EGFR) exon 20 insertion mutations to reduce the uncontrolled growth of cancer cells.
  

• Hanley, M. J., Camidge, D. R., Fram, R. J., & Gupta, N. (2024). Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and Translational Science, 17(3), e13766.
  
• Russell, M. C., Garelli, A. M., & Reeves, D. J. (2023). Targeting EGFR exon 20 insertion mutation in non–small cell lung cancer: amivantamab and mobocertinib. Annals of Pharmacotherapy, 57(2), 198-206.
  
• Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Costa, D. B., ... & Jänne, P. A. (2021). Activity and safety of mobocertinib (TAK-788) in previously treated non–small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial. Cancer discovery, 11(7), 1688-1699.
  
• Yang, J. C. H., Zhou, C., Jänne, P. A., Ramalingam, S. S., Kim, T. M., Riely, G. J., ... & Nguyen, D. (2023). Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer. Expert Review of Anticancer Therapy, 23(1), 95-106.
  
• Gupta, N., Pierrillas, P. B., Hanley, M. J., Zhang, S., & Diderichsen, P. M. (2022). Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer. CPT: Pharmacometrics & Systems Pharmacology, 11(6), 731-744.
  
• Duke, E. S., Stapleford, L., Drezner, N., Amatya, A. K., Mishra-Kalyani, P. S., Shen, Y. L., ... & Donoghue, M. (2023). FDA approval summary: Mobocertinib for metastatic non–small cell lung cancer with EGFR Exon 20 Insertion Mutations. Clinical Cancer Research, 29(3), 508-512.​